Solsence Q2 Net Income Soars 212% on Strong Product Revenue Growth

Ticker: SLSN · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 883107

Sentiment: bullish

Topics: Skincare, Life Sciences, Advanced Materials, Nasdaq Uplisting, Revenue Growth, Net Income Growth, Related Party Debt

TL;DR

**SLSN is crushing it with triple-digit net income growth and a cash injection, making it a strong buy for growth-focused traders.**

AI Summary

SOLESENCE, INC. (SLSN) reported a significant increase in revenue and net income for the three and six months ended June 30, 2025. Product revenue for the three months ended June 30, 2025, surged to $20.261 million from $12.923 million in the prior year, a 56.7% increase. Net income for the quarter jumped to $2.667 million ($0.04 per diluted share) from $856,000 ($0.01 per diluted share) in the same period last year, a 211.6% increase. For the six months ended June 30, 2025, total revenue reached $34.984 million, up from $22.914 million in 2024, and net income rose to $2.747 million from $1.747 million. The company's cash position improved substantially, with cash increasing to $4.108 million as of June 30, 2025, from $1.409 million at December 31, 2024. This was largely driven by $11.849 million in net cash provided by financing activities, including $6.099 million from a new line of credit with Beachcorp, LLC. Total assets grew to $59.956 million from $50.002 million, while total current liabilities decreased to $22.536 million from $25.773 million.

Why It Matters

This strong performance indicates SOLESENCE is effectively executing its strategy in the beauty and life sciences markets, particularly with its proprietary Active Stress Defense Technology. The significant revenue and net income growth, coupled with improved cash flow, could attract new investors and strengthen the company's competitive position against rivals in the prestige skincare and advanced materials sectors. For employees, this signals stability and potential for growth, while customers benefit from continued innovation in skin health products. The uplisting to Nasdaq in April 2025 also enhances visibility and liquidity, potentially leading to a higher valuation and broader market recognition.

Risk Assessment

Risk Level: medium — While SOLESENCE shows strong growth, its reliance on related-party financing, specifically $6.099 million from Beachcorp, LLC for accounts receivable and $9.500 million for inventory, introduces a concentration risk. Additionally, the company's accumulated deficit of $97.681 million as of June 30, 2025, despite recent profitability, indicates historical financial challenges that could resurface.

Analyst Insight

Investors should consider initiating or increasing a position in SLSN, given the substantial revenue and net income growth, coupled with strategic market expansion. Monitor the company's progress in reducing its reliance on related-party financing and its ability to sustain profitability to further de-risk the investment.

Financial Highlights

debt To Equity
1.06
revenue
$34.984M
operating Margin
6.2%
total Assets
$59.956M
total Debt
$20.232M
net Income
$2.747M
eps
$0.04
gross Margin
26.5%
cash Position
$4.108M
revenue Growth
+52.7%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue$34.836M+56.7%
Other Revenue$0.148M-32.7%

Key Numbers

Key Players & Entities

FAQ

What were Solsence's key financial results for the quarter ended June 30, 2025?

For the three months ended June 30, 2025, Solsence reported product revenue of $20.261 million, a 56.7% increase from $12.923 million in the prior year. Net income for the quarter was $2.667 million, a significant jump from $856,000 in the same period of 2024.

How did Solsence's cash position change during the first half of 2025?

Solsence's cash balance increased to $4.108 million as of June 30, 2025, from $1.409 million at December 31, 2024. This increase was primarily due to $11.849 million in net cash provided by financing activities.

What is Solsence's primary business focus?

Solsence, Inc. is a science-driven company focused on beauty- and life-science markets. Its core business revolves around skin health and medical diagnostics, offering engineered materials, formulation development, and commercial manufacturing, particularly for sunscreens and prestige skincare products.

What is Active Stress Defense Technology and how does it impact Solsence?

Active Stress Defense Technology is a suite of three proprietary, mineral-based technologies (Original Active Stress Defense, Kleair, and Bloom) that improve performance and aesthetics in personal care products. It is the cornerstone of Solsence's new product development in personal care and is utilized by its Solsence beauty science subsidiary to manufacture and sell developed solutions.

What was the impact of Solsence's uplisting to Nasdaq?

On April 8, 2025, Solsence's securities were uplisted to Nasdaq, trading under the symbol SLSN. Prior to this, its common stock traded on the OTCQB marketplace under the symbol NANX. The uplisting generally enhances market visibility, liquidity, and investor confidence.

What are the key risks associated with Solsence's financial condition?

A key risk is the company's reliance on related-party financing, with $6.099 million from Beachcorp, LLC for accounts receivable and $9.500 million for inventory as of June 30, 2025. Additionally, despite recent profitability, Solsence still carries an accumulated deficit of $97.681 million.

How has Solsence's total assets and liabilities changed?

Total assets for Solsence increased to $59.956 million as of June 30, 2025, from $50.002 million at December 31, 2024. Concurrently, total current liabilities decreased to $22.536 million from $25.773 million over the same period.

What was Solsence's net income per share for the three months ended June 30, 2025?

Solsence reported basic and diluted net income per share of $0.04 for the three months ended June 30, 2025. This compares to $0.02 basic and $0.01 diluted per share for the same period in 2024.

Does Solsence qualify as a smaller reporting company?

Yes, Solsence qualifies as a smaller reporting company under SEC Release 33-10513; 34-83550, Amendments to Smaller Reporting Company Definition. This allows the company to scale some of its disclosures of financial and non-financial information in its reports.

What is the nature of Solsence's 'other revenue'?

Solsence's 'other revenue' typically includes fees from various required laboratory tests, technology license fees, and paid development projects. These activities are not expected to drive the long-term growth of the business and are recognized over time as obligations are performed.

Risk Factors

Industry Context

Solsence operates in the beauty and life-science markets, focusing on skin health and medical diagnostics. The company leverages materials science and nanotechnology for product development and manufacturing. The beauty and personal care market is highly competitive and trend-driven, while the medical diagnostics sector is subject to stringent regulatory oversight and evolving technological demands.

Regulatory Implications

Operating in the beauty and life-science sectors exposes Solsence to regulatory scrutiny regarding product safety, efficacy, and ingredient sourcing. Compliance with FDA and similar international bodies is critical. Changes in regulations or failure to comply could significantly impact product development, market access, and financial performance.

What Investors Should Do

  1. Monitor related party financing
  2. Analyze revenue drivers
  3. Evaluate operating expense management
  4. Assess cash flow from operations

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Solsence has reduced its accumulated deficit from $(100.428M) to $(97.681M), indicating a move towards profitability.)
Line of credit – accounts receivable, related party
A financing arrangement where a company borrows money against its outstanding accounts receivable, with the lender being a related entity. (Solsence utilized $6.099M from this line, highlighting its importance for short-term liquidity.)
Line of credit – inventory, related party
A financing arrangement where a company borrows money against its inventory, with the lender being a related entity. (The company has a $9.500M long-term portion of this credit line, indicating significant inventory financing.)
Deferred revenue
Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. (Deferred revenue decreased significantly from $5.571M to $2.169M, suggesting that previously booked revenue has been recognized.)
Stock-based compensation
Compensation provided to employees in the form of stock or stock options. (This is a non-cash expense that impacts net income and is adjusted for in cash flow from operations.)

Year-Over-Year Comparison

Solsence has demonstrated robust top-line growth, with total revenue increasing by approximately 52.7% for the six months ended June 30, 2025, compared to the prior year. Net income also saw a substantial rise of 57.2%. The company has significantly improved its cash position, largely due to new financing activities, including a substantial line of credit from Beachcorp, LLC. Total assets have grown, while total current liabilities have decreased, indicating improved short-term financial health. However, operating cash flow remains negative, a trend that needs to be watched.

Filing Stats: 4,668 words · 19 min read · ~16 pages · Grade level 15.4 · Accepted 2025-08-14 16:30:18

Key Financial Figures

Filing Documents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Consolidated Balance Sheets (Unaudited Consolidated Condensed) as of June 30, 2025, and December 31, 2024 3 Consolidated Statements of Operations (Unaudited Consolidated Condensed) for the three a nd six months ended J une 30, 2025, and 2024 4 Consolidated Statements of Shareholders' Equity (Unaudited Consolidated Condensed) for the three and six months ended June 30, 2025, and 2024 5 Consolidated Statements of Cash Flows (Unaudited Consolidated Condensed) for the three and six months ended June 30, 2025, and 2024 6 Notes to Unaudited Consolidated Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 16 Item 4.

Controls and Procedures

Controls and Procedures 16

– OTHER INFORMATION

PART II – OTHER INFORMATION 16 Item 1.

Legal Proceedings

Legal Proceedings 16 Item 1A.

Risk Factors

Risk Factors 16 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 16 Item 3. Defaults Upon Senior Securities 16 Item 4. Mine Safety Disclosures 16 Item 5. Other Information 16 Item 6. Exhibits 17

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements SOLSENCE, INC. CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) As of June 30, 2025 December 31, 2024 (in thousands except share and per share data) ASSETS Current assets: Cash $ 4,108 $ 1,409 Trade accounts receivable 12,470 5,655 Allowance for credit losses ( 1,421 ) ( 786 ) Trade accounts receivable, net 11,049 4,869 Inventories, net 19,832 20,267 Prepaid expenses and other current assets 3,781 2,803 Total current assets 38,770 29,348 Equipment and leasehold improvements, net 13,559 12,734 Operating leases, right of use 7,627 7,917 Other assets, net — 3 Total assets $ 59,956 $ 50,002 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Line of credit – accounts receivable, related party $ 6,099 $ — Current portion of line of credit – inventory, related party — 4,000 Current portion of term debt, related party — 1,000 Current portion of operating lease obligations 1,231 1,260 Accounts payable 6,891 9,093 Deferred revenue 2,169 5,571 Accrued expenses 6,146 4,849 Total current liabilities 22,536 25,773 Long-term portion of operating lease obligations 8,482 9,037 Long-term portion of line of credit– inventory, related party 9,500 — Long-term portion of term debt, related party 1,000 — Asset retirement obligations 250 246 Total long-term liabilities 19,232 9,283 Stockholders' equity: Preferred stock, $ .01 par value, 24,088 shares authorized, and no shares issued and outstanding — — Common stock, $ .01 par value, 95,000,000 shares authorized; 70,481,945 and 70,103,279 shares issued and outstanding on June 30, 2025 and December 31 2024, respectively 704 700 Additional paid-in capital 115,165 114,674 Accumulated deficit ( 97,681 ) ( 100,428 ) Total stockholders' equity 18,188 14,946 Total liabilities and stockholders' equity $ 59,956 $ 50,002 (See accompanying Notes to Consolidat

Financial Statements)

Financial Statements) 4 SOLSENCE, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited Consolidated Condensed) (in thousands except share data) Preferred Stock Common Stock Additional Paid-in Accumulated Description Shares Amount Shares Amount Capital Deficit Total Balance on December 31, 2023 — $ — 49,627,254 $ 496 $ 106,069 $ ( 104,663 ) $ 1,902 Issuance of shares and stock option exercises — — 5,233,730 52 1,944 — 1,996 Stock-based compensation — — — — 160 — 160 Net income for the three months ended March 31, 2024 — — — — — 893 893 Balance on March 31, 2024 — — 54,860,984 548 108,173 ( 103,770 ) 4,951 Issuance of shares and stock option exercises — — 15,000,000 150 5,810 — 5,960 Stock-based compensation — — — — 157 — 157 Net income for the three months ended June 30, 2024 — — — — — 856 856 Balance on June 30, 2024 — $ — 69,860,984 $ 698 $ 114,140 $ ( 102,914 ) $ 11,924 Balance on December 31, 2024 — $ — 70,103,279 $ 700 $ 114,674 $ ( 100,428 ) $ 14,946 Issuance of shares and stock option exercises — — — — 3 — 3 Stock-based compensation — — — — 127 — 127 Net income for the three months ended March 31, 2025 — — — — — 80 80 Balance on March 31, 2025 — — 70,103,279 700 114,804 ( 100,348 ) 15,156 Issuance of shares and stock option exercises — — 378,666 4 241 — 245 Stock-based compensation — — — — 120 — 120 Net income for the three months ended June 30, 2025 — — — — — 2,667 2,667 Balance on June 30, 2025 — $ — 70,481,945 $ 704 $ 115,165 $ ( 97,681 ) $ 18,188 (See accompanying Notes to Consolidated

Financial Statements)

Financial Statements) 5 SOLSENCE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Six months ended June 30, 2025 2024 (in thousands) Operating activities: Net income $ 2,747 $ 1,747 Adjustments to reconcile net income to cash used in operating activities: Depreciation and amortization 451 469 Stock-based compensation 247 317 Changes in assets and liabilities related to operations: Trade accounts receivable, net ( 6,180 ) ( 2,465 ) Inventories, net 435 ( 3,843 ) Prepaid expenses and other assets ( 978 ) ( 1,011 ) Accounts payable ( 2,202 ) ( 1,182 ) Accrued expenses 1,301 935 Deferred revenue ( 3,402 ) 724 Change in right of use asset and lease liability, net ( 294 ) ( 111 ) Net cash used in operating activities ( 7,875 ) ( 4,420 ) Investing activities: Acquisition of equipment and leasehold improvements ( 1,275 ) ( 562 ) Net cash used in investing activities ( 1,275 ) ( 562 ) Financing activities: Proceeds from line of credit - inventory, related party 5,500 200 Proceeds from line of credit – accounts receivable, related party 6,099 14,875 Payments to line of credit – accounts receivable, related party — ( 15,414 ) Payments to term loans, related party — ( 2,000 ) Proceeds from issuance of mezzanine preferred stock — 6,000 Proceeds from issuance of stock and exercise of stock options 250 1,957 Net cash provided by financing activities 11,849 5,618 Increase in cash 2,699 636 Cash at beginning of period 1,409 1,722 Cash at end of period $ 4,108 2,358 Supplemental cash flow information: Interest paid $ 354 $ 341 Income Taxes Paid $ 325 $ — Supplemental non-cash investing and financing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements $ 499 $ 499 Conversion of mezzanine preferred stock $ — $ 6,000 (See accompanying Notes to Consolidated

Financial Statements)

Financial Statements) 6 SOLSENCE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited Consolidated Condensed) (In thousands, except share and per share data or as otherwise noted herein) (1) Basis of Presentation The accompanying unaudited consolidated condensed interim financial statements of Solsence, Inc. ("Solsence", "Company", "we", "our", or "us") reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Solsence, Inc. and our wholly-owned subsidiary, Solsence, LLC. Operating results for the three and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2024, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission. (2) Description of Business Solsence, Inc. ("Solsence", "Company", "we", "our", or "us") is a science-driven company which, along with its wholly owned subsidiary, Solsence, LLC (our "Solsence beauty science subsidiary"), is focused in various beauty- and life-science markets. Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and "non-nano" scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully develop

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing